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Abstract
Methicillin-resistant S. aureus emerged in recent decades to become a leading cause of infection worldwide. Colonization
with MRSA predisposes to infection and facilitates transmission of the pathogen; however, available regimens are ineffective
at preventing MRSA colonization. Studies of human nasal flora suggest that resident bacteria play a critical role in limiting S.
aureus growth, and prompted us to query whether application of commensal resident bacteria could prevent nasal
colonization with MRSA. We established a murine model system to study this question, and showed that mice nasally pre-
colonized with S. epidermidis became more resistant to colonization with MRSA. Our study suggests that application of
commensal bacteria with antibiotics could represent a more effective strategy to prevent MRSA colonization.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) colonization
poses a major public health problem because it predisposes
colonized individuals to infection and facilitates spread of the
pathogen to close contacts [1]. Attempts to address this problem
have led to the widespread practice of MRSA decolonization both
in healthcare-settings and in the community [1]. However, as a
number of studies have suggested, standard regimens prescribed
by most physicians do not prevent colonization of patients [2]. For
example, individuals who receive a routine course of mupirocin in
the nares and a body wash with hexachlorophene are frequently
found to be colonized within few months, especially in the setting
of close contact with MRSA colonizers [2]. While extended
application of nasal mupirocin can be more effective, it leads to
unacceptable level of mupirocin resistance [1,3]. Based on studies
of available regimens, currently there is no effective solution to
prevent MRSA colonization.
An approach that showed promise in the 1960’s was a strate-
gy called bacterial interference [4], in which a less virulent S. aureus
strain was used to block colonization by pathogenic S. aureus strains.
Application of this strategy in the setting of S. aureus outbreaks
proved to be effective, as patients treated with the ‘‘nonpatho-
genic‘‘ 502A S. aureus strain showed a significant decrease in
infection rate in multiple trials [4]. Unfortunately 502A was
eventually linked to cases of S. aureus infections, and therefore
enthusiasm for this strategy was dampened [5].
Notwithstanding the results of these investigations, many studies
since have shown that select resident bacteria actively compete
against S. aureus for survival on human skin and mucosal surfaces
[6,7,8]. For example, following introduction of the seven-valent
pneumococcal vaccine, researchers noted increased S. aureus
colonization and infection among vaccinees, suggesting that
removal of S. pneumoniae from the human nose permitted S. aureus
to colonize more freely [6,9]. We recently showed that S. aureus
elaboration of catalase protected the pathogen from killing by S.
pneumoniae [10]. However, even with the expression of catalase, S.
aureus resistance to S. pneumoniae killing is limited [10,11].
Human studies have also confirmed that nasal commensal
bacteria such as S. epidermidis and Corynebacterium spp. compete with
S. aureus for the same niche, as presence of one often predicts
absence of the other in the same individual [8,12,13]. In our study,
we showed that intranasal application of S. epidermidis, which
secretes Esp [13], prevented S. aureus nasal colonization. These
findings prompted us to ask whether the current regimen,
consisting of the use of topical antibiotics, could be improved by
co-administration of a competing commensal bacterium to prevent
MRSA colonization.
Results
Establishment of the murine experimental model
To determine whether application of commensal bacteria could
prevent nasal colonization of mice with MRSA, we first tested a
number of candidate strains for intranasal survival. We reasoned
that bacteria that could compete successfully against MRSA must
first colonize the nose at high concentration. Prior studies have
suggested that both Corynebacterium spp. and S. epidermidis interfere
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In Figure 1A, we inoculated the nose of CD1 mice with 2 strains of
Corynebacterium spp. and 2 strains of S. epidermidis, and sacrificed the
mice after 3 days to enumerate surviving nasal CFU. Based on this
experiment, S. epidermidis NRS122 colonized the nares of mice as
well or better than the other strains, and was therefore selected as
our candidate strain.
In preliminary experiments, we noted that both MRSA and S.
epidermidis colonize the nose of 8–12 week old mice poorly. To fine-
tune our murine model and optimize nasal S. epidermidis and
MRSA colonization, we next investigated the impact of age of the
host. In a prior study, our lab has demonstrated that 6 month old
mice show a more limited immune response and carry a higher S.
aureus burden compared to 8–12 week old mice following a
subcutaneous infection [14]. Therefore we speculated that it would
be possible to increase S. epidermidis (and MRSA) colonization using
6 month old mice. We applied S. epidermidis NRS122 to the nares
of 6–12 week old mice and 6 month old mice, and showed that the
nares of 6 month old mice were more prominently colonized with
NRS122 compared to 6–12 week old mice after 3 days (5560
versus 770 CFU: p,0.05; n=4–5 per group).
Next we sought to simulate the clinical scenario in which
patients received an antibiotic as part of the decolonizing regimen,
and to investigate whether application of S. epidermidis protected
from MRSA colonization. The use of topical mupirocin (used
routinely in human) is impractical in mice because of the narrow
opening of nares which prevented consistent application of the
thick antibiotic gel. Therefore, we elected instead to use oral
streptomycin, an antibiotic that effectively cleared the endogenous
nasal flora in mice [15]. To verify that application of streptomycin
does not lead to inadvertent killing of the competing S. epidermidis,
we streaked NRS122 on streptomycin agar plates (THA with
500 mg/ml streptomycin), and isolated colonies of NRS122 that
are resistant to streptomycin. Next, we treated mice orally with
normal drinking water or water supplemented with 1000 mg/ml
streptomycin for 7 days. On day 3 after the initiation of
streptomycin, we inoculated both groups of mice with the
streptomycin-resistant S. epidermidis NRS122 once a day for 3
consecutive days. As shown in Figure 1B, mice receiving the
antibiotic water, showed significantly higher S. epidermidis
NRS122 CFU in the nose compared to mice receiving water
alone, consistent with prior findings that clearance of endogenous
flora facilitates colonization of nasally applied bacteria [15].
Prophylactic application of S. epidermidis prevents MRSA
colonization
Using these optimized conditions, we investigated whether
application of NRS122 could effectively reduce nasal colonization
by MRSA. For the experiment, we pretreated mice with
streptomycin, then inoculated one group intranasally with PBS,
and the other group with streptomycin-resistant S. epidermidis
NRS122. After two days, the mice were administered streptomy-
cin-resistant MRSA by the intranasal route, and sacrificed after
another 2 days. As shown in Figure 2, the mice that received
streptomycin plus NRS122 showed reduced colonization with the
MRSA compared to the mice that received streptomycin alone
(Mean: 673 versus 4715; Median: 390 versus 1170). The number
of competing NRS122 at the time of harvest was 12953.
Discussion
The current study was undertaken to establish a murine model
and to provide proof of principle that a probiotic strategy could
prevent MRSA colonization in setting of close contact with MRSA
colonizers such as nursing homes. It has been well documented
that use of nasal mupirocin provides only short term eradication of
MRSA in patients previously colonized with MRSA [2]. Within
months, patients are colonized at the same rate as those who did
not receive mupirocin treatment [2]. Mupirocin is active against a
wide range of Gram-positive bacteria and many Gram-negative
bacteria [16]. Therefore, application of the topical antibiotic could
lead to eradication of the endogenous nasal flora, and without
replacement flora, would permit MRSA to colonize. Alternatively,
individuals who receive antibiotic treatment for any infection
could become susceptible to MRSA colonization because of
eradication of competing nasal flora.
Studies in the 1960’s have shown that a less pathogenic S. aureus
strain could be used to successfully outcompete the epidemic S.
aureus strain [4]. Yet, the inherent danger associated with the
application of a pathogen to displace another pathogen makes that
an impractical approach [5], and led to the abandonment of that
Figure 1. Optimizing conditions for bacterial interference. (A)
Efficacy of nasal colonization by four strains of bacteria. CD1 mice were
inoculated with 1610
9 CFU on d1 and 4. Nasal CFU was enumerated 3
days after the last inoculation. Corynebacterium spp. 1 versus NRS122:
p,0.05. (B) Effect of oral streptomycin treatment on S. epidermidis
NRS122 nasal colonization. Mice were given streptomycin water for 7
days, then inoculated with a streptomycin-resistant strain of NRS122
daily for 3 days. Nasal CFU were harvested 3 days later. Shown are total
CFU or CFU from streptomycin plates. Bars in the graph represent the
median CFU of each experimental group.
doi:10.1371/journal.pone.0025880.g001
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prevention and treatment of a number of human gastrointestinal
conditions have demonstrated that application of non-pathogens is
relatively safe and likely more acceptable if applied for prevention
of nasal MRSA colonization.
In the current study, we demonstrated that presence of an
applied probiotic could prevent nasal colonization with MRSA.
We showed that intranasal administration of a S. epidermidis strain
reduced MRSA colonization two days later. From a translational
viewpoint, this could be construed to be a preventative strategy for
an acute MRSA outbreak. However it begs the greater question
whether this could also represent a long term strategy that prevents
MRSA colonization months later in high risk settings such as
nursing homes. For that purpose, our data only support the
concept that if there are sufficient competitor bacteria present at
the time of MRSA exposure, the host will be less susceptible to
nasal colonization with MRSA. However, the mouse model has its
limitation for long term studies: Neither S. epidermidis nor MRSA
colonize mice at high concentration or for an extended period of
time, thereby limiting our ability to address that question. But even
without additional animal data, existing published studies suggest
that the strategy could work. For example, multiple studies have
identified the antagonistic relationship of S. aureus versus
Corynebacterium spp. or S. epidermidis: It has been shown that
presence of Corynebacterium spp. or S. epidermidis often predicts the
absence of the other species in human noses [8,12]. In a
longitudinal study of 166 premature infants in a neonatal intensive
care unit, it has been shown that presence of viridans group
streptococci in the first 2 weeks of life correlated with protection
from MRSA colonization at the time of discharge from the
hospital (9.5% versus 44.7%) [7].
Furthermore, in a study carried out at Nagano Children’s
Hospital, Japan, Uehara and coworkers enlisted the participation
of 17 human healthcare volunteers who were persistently
colonized with S. aureus [12]. They applied Corynebacterium spp. to
the nares of these individuals and showed that inoculation of the
competing bacteria led to S. aureus decolonization in 71% of the
individuals [12]. The authors noted that S. aureus recolonization
was not observed when the subjects were followed for 3–35
months suggesting that bacterial interference could lead to long-
term decolonization. However, there were no control subjects to
evaluate the rate of recolonization in subjects not given
corynebacterium spp.
Among the key factors that are believed to play a role in inter-
bacterial competition, binding to host receptors and secretion of
bacteriocins are perceived to be important strategies used by
competing microbes [1,11]. Certain bacteria such as H. influenzae
induce the recruitment of immune cells to drive the clearance of
their niche competitor, S. pneumoniae [17]. It has been proposed
that S. aureus and S. epidermidis limit cross-competition by secreting
autoinducing (quorum sensing) peptides (AIPs) [18]. There are 4
alleles of AIPs corresponding to four distinct agr groups, and these
Figure 2. Pre-colonization of mouse nares with S. epidermidis NRS122 reduces colonization with MRSA. Top panel: Experimental design.
Bottom panel: Comparison of MRSA colonization in mice given streptomycin water and pretreated with either PBS or S. epidermidis NRS122.
Streptomycin-resistant strains of MRSA and NRS122 (5610
8 CFU) were applied at each inoculation. Bars in the graph represent the median CFU of
each experimental group. Mean bacterial counts were 4715 CFU of MRSA in the control group, and 673 CFU of MRSA and 12953 of NRS122 in the S.
epidermidis NRS122 pretreated group.
doi:10.1371/journal.pone.0025880.g002
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colonization. The cognate peptide from one agr group, upon
secretion, activates agr expression in the same agr group but could
inhibit agr expression in other staphylococcal groups. Therefore
this could be a basis for suppression of colonization among
staphylococcal species [18].
Our recently published study indicated that a subset of S.
epidermidis secretes Esp, which inhibits S. aureus biofilm formation
and destroys pre-existing S. aureus biofilms, and hinders S. aureus
nasal colonization by novel interferential mechanisms [13]. In an
assay for Esp, we determined that the interfering strain used in the
present study produced Esp; however, the activity was strikingly
weak (data not shown). Therefore, the interference observed in our
model is likely due to another factor in addition to Esp. Future
experiments will explore the relative contribution of various
mechanisms towards bacterial interference using S. epidermidis and
other probiotic strains. Such studies will provide interesting
information for developing future therapies.
In summary, the emergent MRSA epidemic and the lack of a
successful preventive strategy prompts the question of whether the
timing may be ripe for re-evaluation of bacterial interference. The
‘‘probiotic’’ regimen, as determined by the bacteria to be included
in the probiotic cocktail and the frequency of administration,
requires further optimization, preferably in an animal model as
established in this study. Because MRSA can colonize sites outside
the nose, the efficiency of this approach towards preventing
colonization elsewhere will also need to be evaluated. However,
unlike antibiotics, which can become obsolete over time due to
acquisition of resistance, bacterial interference may be more
durable. In the absence of a vaccine, a probiotic applied
intranasally and possibly outside the nose may offer a long-term
solution not addressed by current MRSA preventative regimens.
Materials and Methods
Ethics Statement
All animal experiments were approved by the Cedars-Sinai
Committee on the Use and Care of Animals and performed using
accepted veterinary standards (IACUC protocol 2052).
Bacterial strains, media, mice, and reagents
S. epidermidis NRS8 and NRS122 were obtained from the
NARSA repository (www.narsa.net). Corynebacterium spp. strains 1
and 2 were skin isolates obtained from the Cedars-Sinai clinical
laboratory. MRSA BD02-31 is a pulse-type USA500 strain
(courtesy of Dr. Binh Diep). S. epidermidis and S. aureus strains
were cultured at 37uC in either Todd-Hewitt broth (THB) or on
Todd-Hewitt agar (THA) (Difco). Brain Heart Infusion (BHI)
(Difco) broth and agar were used to grow Corynebacterium spp.
When included, streptomycin sulfate salt (Sigma-Aldrich) was
added to bacterial growth media at 500 mg/ml or to antibiotic
water at 1000 mg/ml. CD1 mice were purchased from Charles
River Laboratories, Wilmington, MA.
Selection of streptomycin-resistant S. epidermidis and
MRSA
S. epidermidis NRS122 and MRSA BD02-31 were grown
overnight in THB, washed once in PBS (Dulbecco), and plated
on THA with streptomycin (500 mg/ml). Streptomycin-resistant
strains were isolated from the plates two days later. These strains
were maintained and grown in streptomycin prior to in vivo studies.
Murine nasal colonization studies
Bacteria used for nasal inoculation were cultured for 18–24 h in
THB with or without streptomycin (500 mg/ml), and washed once
in PBS. Mice were inoculated intranasally with 10 ml droplet of the
inocula at the indicated concentrations. For bacterial enumera-
tion, the mice were euthanized using isoflurane followed by
cervical dislocation, and the nasal tissue was homogenized and
vortexed for 5 min in PBS, and the homogenate was plated on
THA with or without streptomycin after appropriate serial
dilutions. Bacterial identification was based on antibiotic resistance
patterns, colony morphology, and color as previously described
[10]. Briefly, we have shown that mice (n=5) administered PBS
alone in the nose, harbor on average 1.9610
6 CFU per nose, but
none of the endogenous bacteria grew on streptomycin (500 mg/
ml) plates (Figure S1). Therefore, the inoculated streptomycin-
resistant S. epidermidis NRS122 and MRSA BD02-31 could be
clearly distinguished from the endogenous flora by growth on
streptomycin plates. S. epidermidis NRS122 could be differentiated
from MRSA BD02-31 on the basis color (white versus orange) on
THA plates.
Statistical analysis
Data were analyzed using Prism 4.03 (Graphpad Software, Inc.)
and Excel (Microsoft). The results of the in vivo challenge studies
were evaluated using the Mann-Whitney test. The Kruskal-Wallis
test was used when three or more groups of data were compared.
Unless otherwise indicated, a p value less than 0.05 was considered
significant, and noted in the figures.
Supporting Information
Figure S1 Endogenous nasal bacteria from mice are
susceptible to streptomycin. CD1 mice (n=5) were admin-
istered PBS intranasally daily for 3 days. On day 4, bacteria from
the nares were plated on THA with or without streptomycin
(500 mg/ml) plates.
(TIF)
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